Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yun‑Min Lu"'
Autor:
Shao-Jun Chu, Ge Wang, Peng-Fei Zhang, Rui Zhang, Yan-Xia Huang, Yun-Min Lu, Wei Da, Qun Sun, Jing Zhang, Jin-Shui Zhu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-1 (2017)
Externí odkaz:
https://doaj.org/article/18fcd91850e84afcb66ad116fc2ad2fa
Publikováno v:
Molecular Medicine Reports. 2016, Vol. 13 Issue 3, p2235-2240. 6p.
Autor:
Yun-Min Lu, Peng-Fei Zhang, Qun Sun, Wei Da, Jin-Shui Zhu, Rui Zhang, Ge Wang, Jing Zhang, Yan-Xia Huang
Publikováno v:
Journal of Cellular and Molecular Medicine
Sanguinarine, a bioactive benzophenanthridine alkaloid extracted from plants of the Papaveraceae family, has shown antitumour effects in multiple cancer cells. But the therapeutic effects and regulatory mechanisms of sanguinatine in gastric cancer (G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85877d7c6699d69e7ef3c1978c2272e
https://doi.org/10.1111/jcmm.13043
https://doi.org/10.1111/jcmm.13043
Autor:
Ge Wang, W.W. Lu, Jing Zhang, Rui Zhang, Shao-Jun Chu, L.Q. Xia, Qun Sun, Yun-Min Lu, Wei Da, Jin-Shui Zhu
Publikováno v:
Oncotarget
Accumulating evidence shows that large tumor suppressor 1 (LATS1) as a novel resident governor of cellular homeostasis is implicated in multiple tumorigenic properties including cell growth, apoptosis and metastasis. However, the contribution of LATS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d979ad6c51cc1f296213dffff3bd704f
http://europepmc.org/articles/PMC4941306
http://europepmc.org/articles/PMC4941306
Autor:
Yuan-Fei Liu1 wangyang163jed@163.com, Yun-Min Lu1 203230@sjtu.edu.cn, Guo-Qiang Qu1 wyjedsw@163.com, Yuan Liu1 wyjrdsw@163.com, Wei-Xiong Chen1 wyjrdwz@163.com, Xiao-Hong Liao1 wyjedwz@163.com, Wu-Ming Kong1 wangyang163jrd@163.com
Publikováno v:
International Journal of Molecular Sciences. 2015, Vol. 16 Issue 1, p1576-1589. 14p. 6 Graphs.
Publikováno v:
Microbial Pathogenesis. 142:104104
Patients with inflammation in the terminal ileum have high morbidity. In genetically susceptible hosts, chronic intestinal inflammation targeting the resident intestinal microbiota develops, but the microbial signature of the terminal ileum is poorly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81f993f920223180321e9a145f801159
https://doi.org/10.1016/j.micpath.2020.104104
https://doi.org/10.1016/j.micpath.2020.104104
Autor:
Yun‑Min Lu, Yuan‑Fei Liu, Yuan Liu, Xiao‑Hong Liao, Wu‑Ming Kong, Guo‑Qiang Qu, Wei-Xiong Chen
Publikováno v:
Molecular Medicine Reports
Gastric cancer (GC) is the second most common cause of cancer-associated mortality worldwide. Previous studies suggest that mitogen-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) is involved in cancer cell growth, apoptosis and migr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012033b8a0da483b6d72ace7ac94370d
http://europepmc.org/articles/PMC4686070
http://europepmc.org/articles/PMC4686070
Publikováno v:
International Journal of Oncology. 47:1767-1774
AKT/GSK-3β/β-catenin signaling pathway plays an important role in the progression of colorectal cancer (CRC). Toosendanin (TSN) is a triterpenoid extracted from the bark or fruits of Melia toosendan Sieb et Zucc and possesses antitumour effects on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36d169f2da0ee6afee9f210a1b35a14b
https://doi.org/10.3892/ijo.2015.3157
https://doi.org/10.3892/ijo.2015.3157
Publikováno v:
International Journal of Immunopathology and Pharmacology. 27:543-551
High mobility group box 1 (HMGB1) has been proved to be implicated in a variety of cell physiological and pathological behaviors including immune response, inflammation and cancer. Accumulating evidence suggests that HMGB1 plays a critical role in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bace97e6477ec20943d82a979cbf2fe
https://doi.org/10.1177/039463201402700410
https://doi.org/10.1177/039463201402700410
Publikováno v:
European Journal of Gastroenterology & Hepatology. 25:885-891
The tumor necrosis factor inhibitors infliximab and adalimumab are effective treatments for Crohn's disease (CD); however, some patients treated with infliximab experience a loss of efficacy. There is a lack of high-quality evidence available on whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c59294648ab6219e54e41b398a833f5
https://doi.org/10.1097/meg.0b013e32836220ab
https://doi.org/10.1097/meg.0b013e32836220ab